Analysis of glycoprotein hormone receptor extracellular domain interactions using a solid-phase capture assay

Stevis, Panayiotis E.; Deecher, Darlene C.

doi:10.1016/j.ab.2004.11.036

Cited by 2 publications

(2 citation statements)

References 23 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They can be used in some conventional assays ranging from drug residues to environmental monitoring. [1][2][3][4][5][6] However, due to their low recognition ability, researchers usually associate the use of these conventional sorbents with instruments which have a re-separation capability and are highly sensitive, e.g. LC/MS, 7-9 GC/MS, [10][11][12][13] MS n .…”

Section: Introductionmentioning

confidence: 99%

Synthesis of molecularly imprinted co-polymers for recognition of ephedrine

et al. 2013

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Synthesis of molecularly imprinted co-polymers for recognition of ephedrine

et al. 2013

View full text Add to dashboard Cite

“…Another second and complementary approach is to link two peptides that can concurrently bind to both the ectodomain (ECD) and trans-membrane domain (BI-10) of the G-protein receptor (intra-bivalency or allosteric/orthosteric dimers), where the former is responsible for specificity and high affinity while the later initiates receptor activation [ 30 ]. Other peptides targeting the ECD with high specificity have been reported to have binding affinities in the low micro-molar levels (5–20 times that of BI-10) [ 63 ], while non-peptide agonists report EC50 in the low nano-molar range [ 64 ]. For these latter compounds, their large size and complex chemical synthesis in addition to their agonist functionality are disadvantages.…”

Section: Discussionmentioning

confidence: 99%

Development of Follicle-Stimulating Hormone Receptor Binding Probes to Image Ovarian Xenografts

Lee

Guo

Matei

et al. 2015

J Biotechnol Biomater

View full text Add to dashboard Cite

The Follicle-Stimulating Hormone Receptor (FSHR) is used as an imaging biomarker for the detection of ovarian cancer (OC). FSHR is highly expressed on ovarian tumors and involved with cancer development and metastatic signaling pathways. A decapeptide specific to the FSHR extracellular domain is synthesized and conjugated to fluorescent dyes to image OC cells in vitro and tumors xenograft model in vivo. The in vitro binding curve and the average number of FSHR per cell are obtained for OVCAR-3 cells by a high resolution flow cytometer. For the decapeptide, the measured EC50 was 160 μM and the average number of receptors per cell was 1.7 × 107. The decapeptide molecular imaging probe reached a maximum tumor to muscle ratio five hours after intravenous injection and a dose-dependent plateau after 24–48 hours. These results indicate the potential application of a small molecular weight imaging probe specific to ovarian cancer through binding to FSHR. Based on these results, multimeric constructs are being developed to optimize binding to ovarian cells and tumors.

show abstract

Analysis of glycoprotein hormone receptor extracellular domain interactions using a solid-phase capture assay

Cited by 2 publications

References 23 publications

Synthesis of molecularly imprinted co-polymers for recognition of ephedrine

Synthesis of molecularly imprinted co-polymers for recognition of ephedrine

Development of Follicle-Stimulating Hormone Receptor Binding Probes to Image Ovarian Xenografts

Contact Info

Product

Resources

About